General information about company | |
| Name of The Company | Tatva Chintan Pharma Chem Limited |
| BSE Scrip Code | 543321 |
| NSE Symbol | TATVA |
| MSE Symbol | NOTLISTED |
| Date of Start of Financial Year | 01-04-2021 |
| Date of End of Financial Year | 31-03-2022 |
| Reporting Period | Second half yearly |
| Date of Start of Reporting Period | 01-10-2021 |
| Date of End of Reporting Period | 31-03-2022 |
| Level of rounding used in financial results | Millions |
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? | Yes |
Related party transactions | |||||||||||||||||||||||
A. Details of related party | Sr | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | ||
| Name of the related party | Tatva Chintan USA Inc. | Tatva Chintan Europe B.V | Shital Chintan Shah | Priti Ajaykumar Patel | Kajal Shekhar Somani | Apurva Dubey | Ashok Bothra | Ishwar Ramanbhai Nayi | Ajaykumar Mansukhlal Patel | Chintan Nitinkumar Shah | Shekhar Rasiklal Somani | Ajaykumar Mansukhlal Patel | Chintan Nitinkumar Shah | Shekhar Rasiklal Somani | Priti Ajaykumar Patel | Kajal Shekhar Somani | Ajay Mansukhlal Patel HUF | Darshana Nitinkumar Shah | Shitalbhai Rasiklal Somani | Samirkumar Rasiklal Somani | |||
| Categories of related parties | Subsidiaries | Subsidiaries | Promoters Group | Promoters Group | Promoters Group | Key management personnel of entity or parent | Key management personnel of entity or parent | Key management personnel of entity or parent | Key management personnel of entity or parent | Key management personnel of entity or parent | Key management personnel of entity or parent | Promoters | Promoters | Promoters | Promoters Group | Promoters Group | Promoters Group | Promoters Group | Promoters Group | Promoters Group | |||
| description of relationship | Wholly owned Subsidiary | Wholly owned Subsidiary | Executive Marketing | Executive Marketing | Executive Marketing | Company Secretary & Compliance Officer (Till - 17.01.2022) | Chief Financial Officer (with effect from 03.12.2021) | Company Secretary & Compliance Officer (with effect from 17.01.2022) | Whole-time Director | Managing Director | Whole-time Director | Fees & expense related to IPO as per Prospectus | Fees & expense related to IPO as per Prospectus | Fees & expense related to IPO as per Prospectus | Fees & expense related to IPO as per Prospectus | Fees & expense related to IPO as per Prospectus | Fees & expense related to IPO as per Prospectus | Fees & expense related to IPO as per Prospectus | Fees & expense related to IPO as per Prospectus | Fees & expense related to IPO as per Prospectus | |||
| PAN of related party | ZZZZZ9999Z | ZZZZZ9999Z | AFOPS7110Q | AEDPP1295H | AAKPD0835E | BNCPD4820R | AGFPB9662E | APGPN4130H | ACSPP6803C | AGQPS0271D | AKRPS2524A | ACSPP6803C | AGQPS0271D | AKRPS2524A | AEDPP1295H | AAKPD0835E | AAGHA5159J | ANCPS1560J | ABKPS9106N | ABKPS9105R | |||
| CIN of related party | |||||||||||||||||||||||
B. Details of related party transactions | Purchase of goods and services | ||||||||||||||||||||||
| Sale of goods and services | 279.3491 | 248.4422 | |||||||||||||||||||||
| Purchase of fixed assets | |||||||||||||||||||||||
| Sale of fixed assets | |||||||||||||||||||||||
| Rendering of services | |||||||||||||||||||||||
| Receiving of services | |||||||||||||||||||||||
| Leases | |||||||||||||||||||||||
| Loans and advances given | 0.2829 | ||||||||||||||||||||||
| Loans and advances taken | |||||||||||||||||||||||
| Loans and advances given that are repaid | |||||||||||||||||||||||
| Loans and advances taken that are repaid | |||||||||||||||||||||||
| Deposits placed | |||||||||||||||||||||||
| Deposits taken | |||||||||||||||||||||||
| Transfer of research & development | |||||||||||||||||||||||
| Transfers under lease agreement | |||||||||||||||||||||||
| Equity investment | |||||||||||||||||||||||
| Impairment in equity investment | |||||||||||||||||||||||
| Expense for bad or doubtful debts | |||||||||||||||||||||||
| Guarantees or collateral given | |||||||||||||||||||||||
| Guarantees or collateral taken | |||||||||||||||||||||||
| Interest income | |||||||||||||||||||||||
| Interest paid | |||||||||||||||||||||||
| Dividend income | |||||||||||||||||||||||
| Dividend paid | |||||||||||||||||||||||
| Management contracts including for deputation of employees | |||||||||||||||||||||||
| Settlement of liabilities by entity on behalf of related party | |||||||||||||||||||||||
Remuneration | Short term employee benefits | 0.15 | 0.15 | 0.15 | 0.1352 | 1.5637 | 0.1659 | 8.2516 | 8.2516 | 8.2516 | |||||||||||||
| Post employment benefits | |||||||||||||||||||||||
| Other long-term benefits | |||||||||||||||||||||||
| Termination benefits | |||||||||||||||||||||||
| Share based payments | |||||||||||||||||||||||
| Others | 0.0015 | 0.0061 | 0.0023 | 0.009 | 0.163 | 16.9632 | 59.2621 | 53.1467 | 24.8988 | 8.0084 | 24.8988 | 7.4987 | 0.8008 | 4.7322 | |||||||||
C. Outstanding balances | Receivables | Secured | |||||||||||||||||||||
| Un Secured | 127.6453 | 143.8425 | |||||||||||||||||||||
Payables | Secured | ||||||||||||||||||||||
| Un Secured | 0.2822 | 0.0654 | 0.7632 | 0.7647 | 0.7915 | 0.2553 | 0.892 | 0.7999 | 0.3747 | 0.1205 | 0.3747 | 0.1128 | 0.012 | 0.0712 | |||||||||
Loans and advances given | Secured | ||||||||||||||||||||||
| Un Secured | |||||||||||||||||||||||
Loans and advances taken | Secured | ||||||||||||||||||||||
| Un Secured | |||||||||||||||||||||||
Deposits placed | Secured | ||||||||||||||||||||||
| Un Secured | |||||||||||||||||||||||
Deposits taken | Secured | ||||||||||||||||||||||
| Un Secured | |||||||||||||||||||||||
Guarantees or collateral given | Secured | ||||||||||||||||||||||
| Un Secured | |||||||||||||||||||||||
Guarantees or collateral taken | Secured | ||||||||||||||||||||||
| Un Secured | |||||||||||||||||||||||
Investment in equity | Secured | ||||||||||||||||||||||
| Un Secured | 6.656 | 0.0095 | |||||||||||||||||||||
Provision for doubtful debt | Secured | ||||||||||||||||||||||
| Un Secured | |||||||||||||||||||||||
Note | Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders | Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders | Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders | Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders | Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders | Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders | Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders | Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders | Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders | ||||||||||||||